Revvity, Inc. (RVTY)
- Previous Close
102.09 - Open
101.92 - Bid 101.82 x 1300
- Ask 101.80 x 800
- Day's Range
101.01 - 103.15 - 52 Week Range
79.50 - 132.54 - Volume
803,780 - Avg. Volume
874,319 - Market Cap (intraday)
12.539B - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
70.49 - EPS (TTM)
1.44 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield 0.28 (0.28%)
- Ex-Dividend Date Jul 19, 2024
- 1y Target Est
125.92
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
www.revvity.com11,500
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RVTY
Performance Overview: RVTY
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVTY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVTY
Valuation Measures
Market Cap
12.54B
Enterprise Value
15.00B
Trailing P/E
70.49
Forward P/E
21.79
PEG Ratio (5yr expected)
2.66
Price/Sales (ttm)
4.61
Price/Book (mrq)
1.59
Enterprise Value/Revenue
5.45
Enterprise Value/EBITDA
21.02
Financial Highlights
Profitability and Income Statement
Profit Margin
25.20%
Return on Assets (ttm)
1.72%
Return on Equity (ttm)
2.35%
Revenue (ttm)
2.75B
Net Income Avi to Common (ttm)
179.5M
Diluted EPS (ttm)
1.44
Balance Sheet and Cash Flow
Total Cash (mrq)
1.6B
Total Debt/Equity (mrq)
51.64%
Levered Free Cash Flow (ttm)
1.67B
Research Analysis: RVTY
Company Insights: RVTY
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RVTY
RVTY: Raising target price to $83.00
REVVITY INC has an Investment Rating of SELL; a target price of $83.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRVTY: Lowering target price to $80.00
REVVITY INC has an Investment Rating of SELL; a target price of $80.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRVTY: Raising target price to $89.00
REVVITY INC has an Investment Rating of SELL; a target price of $89.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetMid Cap U.S. Pick List April 2024
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.